Pharma Times -- Pfizer’s investigational agent PF-00299804 has shown an ability to prevent disease progression when given as a first-line treatment in patients with advanced non-small cell lung cancer.
Pharma Times -- Pfizer’s investigational agent PF-00299804 has shown an ability to prevent disease progression when given as a first-line treatment in patients with advanced non-small cell lung cancer.
